HTG Molecular Diagnostics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	2017 - 2012
Net Income	-9.75	-21.59	-17.15	-20.87	-19.3	-16.45	Upgrade
Depreciation & Amortization	0.19	0.59	0.72	1.35	1.74	1.47	Upgrade
Share-Based Compensation	0.28	0.81	1.38	1.81	1.22	0	Upgrade
Other Operating Activities	2.9	1.79	-1.46	1.42	-0.36	1.81	Upgrade
Operating Cash Flow	-6.39	-18.41	-16.51	-16.29	-16.7	-13.17	Upgrade
Capital Expenditures	-0.01	-0.02	-0.64	-0.45	-1.1	-0.95	Upgrade
Acquisitions	-0	0.1	0.01	-0.02	0	0	Upgrade
Change in Investments	-6.84	-27.56	-31.22	-44.12	-66.8	-85.67	Upgrade
Other Investing Activities	6.6	39.9	25.19	63.32	64.4	63.4	Upgrade
Investing Cash Flow	-0.24	12.42	-6.66	18.73	-3.5	-23.22	Upgrade
Common Stock Issued	8.25	9.02	10.67	7.55	20.76	38.28	Upgrade
Share Repurchases	-0	-0	-0	-0	-0	0	Upgrade
Other Financing Activities	-1.86	-0.41	-0.27	1.5	-1.37	-0.15	Upgrade
Financing Cash Flow	6.39	8.6	10.39	9.05	19.39	38.13	Upgrade
Net Cash Flow	-0.22	2.61	-12.8	11.51	-0.81	1.73	Upgrade
Free Cash Flow	-6.39	-18.43	-17.15	-16.75	-17.8	-14.12	Upgrade
Free Cash Flow Margin	-184.14%	-289.51%	-192.58%	-195.88%	-92.68%	-65.68%	Upgrade
Free Cash Flow Per Share	-	-20.73	-29.68	-43.42	-84.09	-92.37	Upgrade

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.